NTX-083 / Neusignal Therapeutics - LARVOL DELTA

AGC and Neusignal Therapeutics Collaborate on the Development of Alzheimer’s Disease Drug Candidate 'NTX-083' (Webwire) - "In this collaboration, AGC provided integrated support for the drug substance of 'NTX-083', an Alzheimer’s disease drug candidate being developed by NTX, covering process development, GMP manufacturing, and regulatory support from the early stages of development. In addition to establishing the manufacturing process for the drug substance, AGC completed the preparation of documentation required for an IND application in the United States. NTX-083 is scheduled to enter clinical trials in the United States in 2026."

Licensing / partnership • New trial • Alzheimer's Disease